Hepatic Intra-arterial and Systemic Chemotherapy Followed by Maintenance Therapy for the Treatment of Cholangiocarcinoma

Overview

Journal Hepat Oncol

Date 2018 Sep 8

PMID 30191053

Citations 1

Authors

Giammaria Fiorentini

Andrea Mambrini

Donatella Sarti

Maurizio Cantore

Luca Mulazzani

Gian Maria Mattioli

Stefano Guadagni

Affiliations

Soon will be listed here.

Abstract

Aim: The aim is to report clinical outcomes of hepatic intra-arterial (IACHT) and systemic chemotherapy (SCHT), followed by gemcitabine-based maintenance therapy (maintenance), for the treatment of relapsed or unresectable cholangiocarcinoma.

Patients & Methods: In this retrospective observational study, 145 cholangiocarcinoma patients were treated with Epirubicin-Cisplatin as IACHT associated with Capecitabine or 5-fluorouracil as SCHT. Maintenance was performed with gemcitabine-based schedule. Toxicity was assessed with NCI-CTCAE and tumor response with RECIST 1.1.

Results: Tumor response was complete in 1%, partial in 20%, stable disease in 48% and progression in 31% of patients (3 months after therapy). The most frequent adverse events were: anemia (24%), nausea and vomiting (33%), alopecia (60%).

Conclusion: Cholangiocarcinoma patients may benefit from IAHCT-SCHT. Maintenance may prolong clinical benefits. ClinicalTrials.gov registry Identifier: NCT01920503.

Citing Articles

Case Report: Cytoreductive Surgery and HIPEC Associated With Liver Electrochemotherapy in a Cholangiocarcinoma Patient With Peritoneal Carcinomatosis and Liver Metastasis Case Report.

Stefano M, Prosperi E, Fugazzola P, Benini B, Bisulli M, Coccolini F Front Surg. 2021; 8:624817.

PMID: 33816544 PMC: 8018578. DOI: 10.3389/fsurg.2021.624817.

References

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

Razumilava N, Gores G . Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2012; 11(1):13-21.e1. PMC: 3596004. DOI: 10.1016/j.cgh.2012.09.009. View

Kalogirou C, Svistunov A, Krebs M, Lausenmeyer E, Vergho D, Riedmiller H . Maintenance monotherapy with Gemcitabine following cisplatin-based primary combination chemotherapy in surgically treated advanced urothelial carcinoma: A matched-pair single institution analysis. Mol Clin Oncol. 2016; 4(4):636-642. PMC: 4812178. DOI: 10.3892/mco.2016.749. View

Ilyas S, Gores G . Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013; 145(6):1215-29. PMC: 3862291. DOI: 10.1053/j.gastro.2013.10.013. View

Valle J, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H . Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2013; 25(2):391-8. DOI: 10.1093/annonc/mdt540. View

Ramirez-Merino N, Aix S, Cortes-Funes H . Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol. 2013; 5(7):171-6. PMC: 3731530. DOI: 10.4251/wjgo.v5.i7.171. View

Nuzzo G, Giuliante F, Ardito F, De Rose A, Vellone M, Clemente G . Intrahepatic cholangiocarcinoma: prognostic factors after liver resection. Updates Surg. 2010; 62(1):11-9. DOI: 10.1007/s13304-010-0007-x. View

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A . Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010; 103(4):469-74. PMC: 2939781. DOI: 10.1038/sj.bjc.6605779. View

Gusani N, Balaa F, Steel J, Geller D, Marsh J, Zajko A . Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg. 2007; 12(1):129-37. DOI: 10.1007/s11605-007-0312-y. View

10.

Walter T, Horgan A, McNamara M, McKeever L, Min T, Hedley D . Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer. 2012; 49(2):329-35. DOI: 10.1016/j.ejca.2012.08.003. View

11.

Hyder O, Marsh J, Salem R, Petre E, Kalva S, Liapi E . Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013; 20(12):3779-86. DOI: 10.1245/s10434-013-3127-y. View

12.

Simon R, Norton L . The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol. 2006; 3(8):406-7. DOI: 10.1038/ncponc0560. View

13.

Rogers J, Law L, Nguyen V, Qiao W, Javle M, Kaseb A . Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014; 5(6):408-13. PMC: 4226829. DOI: 10.3978/j.issn.2078-6891.2014.072. View

14.

Goldie J, Coldman A . A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979; 63(11-12):1727-33. View

15.

Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R . Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer. 2005; 103(7):1402-7. DOI: 10.1002/cncr.20964. View

16.

Boyle P, Ferlay J . Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16(3):481-8. DOI: 10.1093/annonc/mdi098. View

17.

Rubovszky G, Lang I, Ganofszky E, Horvath Z, Juhos E, Nagy T . Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. Eur J Cancer. 2013; 49(18):3806-12. DOI: 10.1016/j.ejca.2013.07.143. View

18.

Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T . Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008; 15(10):2787-94. DOI: 10.1245/s10434-008-0081-1. View

19.

Kuhlmann J, Blum H . Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol. 2013; 29(3):324-8. DOI: 10.1097/MOG.0b013e32835d9dea. View

20.

Gerber D, Schiller J . Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013; 31(8):1009-20. PMC: 3589699. DOI: 10.1200/JCO.2012.43.7459. View